These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 35748435)

  • 1. Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome.
    Vorstman JA; Breetvelt EJ; Duijff SN; Eliez S; Schneider M; Jalbrzikowski M; Armando M; Vicari S; Shashi V; Hooper SR; Chow EW; Fung WL; Butcher NJ; Young DA; McDonald-McGinn DM; Vogels A; van Amelsvoort T; Gothelf D; Weinberger R; Weizman A; Klaassen PW; Koops S; Kates WR; Antshel KM; Simon TJ; Ousley OY; Swillen A; Gur RE; Bearden CE; Kahn RS; Bassett AS;
    JAMA Psychiatry; 2015 Apr; 72(4):377-85. PubMed ID: 25715178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower [
    van Duin EDA; Ceccarini J; Booij J; Kasanova Z; Vingerhoets C; van Huijstee J; Heinzel A; Mohammadkhani-Shali S; Winz O; Mottaghy F; Myin-Germeys I; van Amelsvoort T
    Psychol Med; 2020 Apr; 50(5):799-807. PubMed ID: 30935427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural control energy of resting-state functional brain states reveals less cost-effective brain dynamics in psychosis vulnerability.
    Zöller D; Sandini C; Schaer M; Eliez S; Bassett DS; Van De Ville D
    Hum Brain Mapp; 2021 May; 42(7):2181-2200. PubMed ID: 33566395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Relationships between Dopaminergic, Glutamatergic, and Cognitive Functioning in 22q11.2 Deletion Syndrome: A Cross-Sectional, Multimodal
    van Hooijdonk CFM; Tse DHY; Roosenschoon J; Ceccarini J; Booij J; van Amelsvoort TAMJ; Vingerhoets C
    Genes (Basel); 2022 Sep; 13(9):. PubMed ID: 36140839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An fMRI study of facial emotion processing in children and adolescents with 22q11.2 deletion syndrome.
    Azuma R; Deeley Q; Campbell LE; Daly EM; Giampietro V; Brammer MJ; Murphy KC; Murphy DG
    J Neurodev Disord; 2015; 7(1):1. PubMed ID: 25972975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurodevelopmental Trajectories and Psychiatric Morbidity: Lessons Learned From the 22q11.2 Deletion Syndrome.
    Fiksinski AM; Schneider M; Zinkstok J; Baribeau D; Chawner SJRA; Vorstman JAS
    Curr Psychiatry Rep; 2021 Feb; 23(3):13. PubMed ID: 33625600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autism Spectrum and psychosis risk in the 22q11.2 deletion syndrome. Findings from a prospective longitudinal study.
    Fiksinski AM; Breetvelt EJ; Duijff SN; Bassett AS; Kahn RS; Vorstman JAS
    Schizophr Res; 2017 Oct; 188():59-62. PubMed ID: 28119035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coping Strategies Mediate the Effect of Stressful Life Events on Schizotypal Traits and Psychotic Symptoms in 22q11.2 Deletion Syndrome.
    Armando M; Sandini C; Chambaz M; Schaer M; Schneider M; Eliez S
    Schizophr Bull; 2018 Oct; 44(suppl_2):S525-S535. PubMed ID: 29548017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disrupted anatomic networks in the 22q11.2 deletion syndrome.
    Schmitt JE; Yi J; Calkins ME; Ruparel K; Roalf DR; Cassidy A; Souders MC; Satterthwaite TD; McDonald-McGinn DM; Zackai EH; Gur RC; Emanuel BS; Gur RE
    Neuroimage Clin; 2016; 12():420-8. PubMed ID: 27622139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computer-vision analysis of craniofacial dysmorphology in 22q11.2 deletion syndrome and psychosis spectrum disorders.
    Roalf DR; McDonald-McGinn DM; Jee J; Krall M; Crowley TB; Moberg PJ; Kohler C; Calkins ME; Crow AJD; Fleischer N; Gallagher RS; Gonzenbach V; Clark K; Gur RC; McClellan E; McGinn DE; Mordy A; Ruparel K; Turetsky BI; Shinohara RT; White L; Zackai E; Gur RE
    J Neurodev Disord; 2024 Jun; 16(1):35. PubMed ID: 38918700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychosis spectrum symptoms among individuals with schizophrenia-associated copy number variants and evidence of cerebellar correlates of symptom severity.
    Sefik E; Guest RM; Aberizk K; Espana R; Goines K; Novacek DM; Murphy MM; Goldman-Yassen AE; Cubells JF; Ousley O; Li L; Shultz S; Walker EF; Mulle JG
    Psychiatry Res; 2024 May; 335():115867. PubMed ID: 38537595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neural substrates of inhibitory control deficits in 22q11.2 deletion syndrome.
    Montojo CA; Jalbrzikowski M; Congdon E; Domicoli S; Chow C; Dawson C; Karlsgodt KH; Bilder RM; Bearden CE
    Cereb Cortex; 2015 Apr; 25(4):1069-79. PubMed ID: 24177988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A neurogenetic model for the study of schizophrenia spectrum disorders: the International 22q11.2 Deletion Syndrome Brain Behavior Consortium.
    Gur RE; Bassett AS; McDonald-McGinn DM; Bearden CE; Chow E; Emanuel BS; Owen M; Swillen A; Van den Bree M; Vermeesch J; Vorstman JAS; Warren S; Lehner T; Morrow B
    Mol Psychiatry; 2017 Dec; 22(12):1664-1672. PubMed ID: 28761081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome.
    Fiksinski AM; Schneider M; Murphy CM; Armando M; Vicari S; Canyelles JM; Gothelf D; Eliez S; Breetvelt EJ; Arango C; Vorstman JAS
    Am J Med Genet A; 2018 Oct; 176(10):2182-2191. PubMed ID: 30194907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring pathway interactions to detect molecular mechanisms of disease: 22q11.2 deletion syndrome.
    Shin W; Kutmon M; Mina E; van Amelsvoort T; Evelo CT; Ehrhart F
    Orphanet J Rare Dis; 2023 Oct; 18(1):335. PubMed ID: 37872602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Airway anomalies in patients with 22q11.2 deletion syndrome: A scoping review.
    Hankey PB; Ghulmiyyah J; Yeh HW; Tracy M; Arganbright J
    Int J Pediatr Otorhinolaryngol; 2022 Dec; 163():111373. PubMed ID: 36335759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synaptic-dependent developmental dysconnectivity in 22q11.2 deletion syndrome.
    Alvino FG; Gini S; Minetti A; Pagani M; Sastre-Yagüe D; Barsotti N; De Guzman E; Schleifer C; Stuefer A; Kushan L; Montani C; Galbusera A; Papaleo F; Lombardo MV; Pasqualetti M; Bearden CE; Gozzi A
    bioRxiv; 2024 Apr; ():. PubMed ID: 38585897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated regional cerebral blood flow in adults with 22q11.2 deletion syndrome.
    Pasternak M; Shirzadi Z; Mutsaerts HJMM; Boot E; Butcher NJ; MacIntosh BJ; Heung T; Bassett AS; Masellis M
    World J Biol Psychiatry; 2023 Mar; 24(3):260-265. PubMed ID: 35748435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome.
    Bakker G; Caan MW; Vingerhoets WA; da Silva-Alves F; de Koning M; Boot E; Nieman DH; de Haan L; Bloemen OJ; Booij J; van Amelsvoort TA
    PLoS One; 2016; 11(11):e0159928. PubMed ID: 27828960
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.